5/6 Nephrectomy as an Experimental Model for Chronic Kidney Disease: New Vasoactive and Antioxidant Therapeutic Targets
Pharmaceuticals · 26.04.2026 · 19 (5) · 676
DOI: 10.3390/ph19050676 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 26.04.2026. Verfasst von Regina Souza Aires und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centro Acadêmico de Vitória, Universidade Federal de Pernambuco (UFPE), Vitória de Santo Antão 55608-680, PE, Brazil. Die Arbeit nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Council for Scientific and Technological Development, Coordenação de Aperfeicoamento de Pessoal de Nível Superior, Fundação de Amparo à Ciência e Tecnologia de Pernambuco.
Abstract (Originalsprache)
Chronic kidney disease (CKD) is a progressive disorder characterized by declining renal function and increased cardiovascular risk. Experimental models are essential for investigating these mechanisms, and the 5/6 nephrectomy (5/6 Nx) model is widely used to reproduce cardiorenal alterations observed in CKD. This review aims to critically evaluate how effectively the 5/6 Nx model reproduces vasoactive and redox mechanisms relevant for pharmacological testing. A narrative synthesis of experimental studies using the 5/6 Nx model in rodents was performed, focusing on vascular, inflammatory, and oxidative pathways. The 5/6 Nx model reproduces major CKD features, including hypertension, proteinuria, glomerulosclerosis, and cardiovascular remodeling. Early activation of the renin–angiotensin–aldosterone system, endothelin signaling, and sympathetic pathways contributes to vascular dysfunction. Sustained oxidative stress reduces nitric oxide bioavailability and promotes endothelial dysfunction. Dysregulation of natriuretic peptides and increased 20-HETE signaling further contribute to vascular imbalance and remodeling. These alterations occur in a well-defined temporal progression, supporting the use of this model for mechanistic and pharmacological studies. The 5/6 Nx model remains a robust and translationally informative platform for investigating CKD progression, provided that pathway-specific reproducibility and experimental variables are carefully considered.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centro Acadêmico de Vitória, Universidade Federal de Pernambuco (UFPE), Vitória de Santo Antão 55608-680, PE, Brazil.
ORCID-Profile: Regina Souza Aires, Maria da Conceição Correia Silva, Mirelly Cunha da Silva, Alice Valença Araújo, Thyago Moreira de Queiroz
Förderung
- National Council for Scientific and Technological Development
- Coordenação de Aperfeicoamento de Pessoal de Nível Superior
- Fundação de Amparo à Ciência e Tecnologia de Pernambuco
- CNPq
- FACEPE
- CAPES
Zitieren
APA
Aires, R. S., Correia Silva, M. D. C., Barbosa, F. M., da Silva, M. C., Alves, S. M. L., Araújo, A. V., & de Queiroz, T. M. (2026). 5/6 Nephrectomy as an Experimental Model for Chronic Kidney Disease: New Vasoactive and Antioxidant Therapeutic Targets. Pharmaceuticals, 19(5), 676. https://doi.org/10.3390/ph19050676
Vancouver
Aires RS, Correia Silva MDC, Barbosa FM, da Silva MC, Alves SML, Araújo AV, et al. 5/6 Nephrectomy as an Experimental Model for Chronic Kidney Disease: New Vasoactive and Antioxidant Therapeutic Targets. Pharmaceuticals. 2026;19(5):676. doi:10.3390/ph19050676
BibTeX
@article{Aires2026,
author = {Aires, Regina Souza and Correia Silva, Maria da Conceição and Barbosa, Filipe de Melo and da Silva, Mirelly Cunha and Alves, Silvia Maria de Luna and Araújo, Alice Valença and de Queiroz, Thyago Moreira},
title = {5/6 Nephrectomy as an Experimental Model for Chronic Kidney Disease: New Vasoactive and Antioxidant Therapeutic Targets},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {5},
pages = {676},
doi = {10.3390/ph19050676}
}
EUVIMED